Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Urologic Oncology
|
February 17, 2019
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer
Andrew W Hahn, David D Stenehjem, Anitha B Alex, et al.
BMC Urology
|
January 7, 2017
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma
James A Kuzman, David D Stenehjem, Joseph Merriman, et al.
BMC Cancer
|
January 9, 2023
Cancer incidence in immunocompromised patients: a single-center cohort study
Sabrina Ilham, Connor Willis, Kibum Kim, et al.
Investigational New Drugs
|
October 11, 2018
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer
G Weldon Gilcrease, David D Stenehjem, Mark L Wade, et al.
Ecancermedicalscience
|
October 13, 2016
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
David M Gill, David D Stenehjem, Kinjal Parikh, et al.
Journal of Oncology
|
February 18, 2015
Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
Srinivas K Tantravahi, Daniel Albertson, Archana M Agarwal, et al.
Clinical Genitourinary Cancer
|
December 16, 2014
Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors
Erin B Bailey, Srinivas K Tantravahi, Austin Poole, et al.
Journal of Geriatric Oncology
|
December 17, 2023
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty
Meena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
April 25, 2017
Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors
Erin B Bailey, Joseph Merriman, Benjamin Maughan, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 20, 2023
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma
Meena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Urologic Oncology
|
February 17, 2019
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer
Andrew W Hahn, David D Stenehjem, Anitha B Alex, et al.
BMC Urology
|
January 7, 2017
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma
James A Kuzman, David D Stenehjem, Joseph Merriman, et al.
BMC Cancer
|
January 9, 2023
Cancer incidence in immunocompromised patients: a single-center cohort study
Sabrina Ilham, Connor Willis, Kibum Kim, et al.
Investigational New Drugs
|
October 11, 2018
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer
G Weldon Gilcrease, David D Stenehjem, Mark L Wade, et al.
Ecancermedicalscience
|
October 13, 2016
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
David M Gill, David D Stenehjem, Kinjal Parikh, et al.
Journal of Oncology
|
February 18, 2015
Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
Srinivas K Tantravahi, Daniel Albertson, Archana M Agarwal, et al.
Clinical Genitourinary Cancer
|
December 16, 2014
Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors
Erin B Bailey, Srinivas K Tantravahi, Austin Poole, et al.
Journal of Geriatric Oncology
|
December 17, 2023
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty
Meena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
April 25, 2017
Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors
Erin B Bailey, Joseph Merriman, Benjamin Maughan, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 20, 2023
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma
Meena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Page
of 5